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AbstrAct:
Genes that are highly expressed in cancer cells and are essential for their viability are 
attractive targets for the development of novel cancer therapeutics.  Activating transcription 
factor 5 (ATF5) is an anti-apoptotic protein that is highly expressed in malignant glioma 
but not normal brain tissues, and is essential for glioma cell survival.  Recent work 
has revealed an essential survival pathway mediated by ATF5 in malignant glioma; 
pharmacological inhibition of this pathway leads to tumor regression in mice.  ATF5 is also 
highly expressed in a variety of other cancers, and preliminary studies have shown that 
the ATF5-mediated survival pathway is active in diverse human cancer cell lines.  Targeting 
this pathway may therefore have therapeutic implications for the treatment of a wide 
range of cancers.  In this perspective, we summarize recent advances in ATF5 research, 
focusing on its role in promoting cancer and its potential as a target for cancer therapy.
IntroductIon
The mammalian activating transcription factor/
cyclic AMP responsive element-binding (ATF/CREB) 
family of transcription factors comprises a large group 
of proteins whose members have diverse roles in 
development, differentiation, cellular proliferation and 
apoptosis. Members of the ATF/CREB family contain 
related basic leucine zipper (bZIP) domains; the basic 
region is enriched with lysine and arginine residues and 
is involved in DNA binding, whereas the leucine zipper 
motif mediates protein-protein interactions. ATF/CREB 
proteins bind as homo- or hetero-dimers to a DNA-
binding site known as the cyclic AMP responsive element 
(CRE), which has the consensus sequence TGACGTCA 
(reviewed in [1]).
ATF5, previously designated as ATFx (or ATF7 
in  mice),  was  first  isolated  as  a  binding  partner  of 
granulocyte colony-stimulating factor (G-CSF) gene 
promoter element 1-binding protein (GPE1-BP), a protein 
involved in regulating G-CSF expression [2]. Subsequent 
studies have revealed that ATF5 can either homodimerize 
or form heterodimers with ATF4 or CCAAT enhancer-
binding protein (C/EBP), and bind CRE elements [3,4] 
or  a  recently-identified  novel  DNA  motif  with  the 
consensus sequence C(C/T)TCT(T/C)CCTTA [5]. ATF5 
has also been shown to heterodimerize with the human 
T-cell leukemia virus type 1 (HTLV-1) Tax transactivator 
protein and bind to the Tax-responsive element, a member 
of the asymmetric CRE family of enhancer sequences [6].
A role for ATF5 in promoting cell survival was first 
suggested from gene expression profiling analysis in murine 
pro-B lymphocytic cells induced to undergo apoptosis 
following withdrawal of the cytokine interleukin-3 (IL-3) 
[7]. Among the most dramatic changes observed was a 
large decrease in ATF5 expression, raising the possibility 
that ATF5 had a role in cell survival. Subsequent work 
revealed that ATF5 plays a critical role in antagonizing 
apoptosis induced by either the deprivation of IL-3 or 
the expression of a pro-apoptotic protein 24p3 in murine 
pro-B lymphocytes, or by growth factor withdrawal in 
HeLa cells [8].
AtF5 ExprEssIon In cAncEr
In cancer cells, genes that induce apoptosis are 
often inactivated or down-regulated, whereas anti-
apoptotic genes are frequently activated or over-
expressed. Consistent with this paradigm, a number 
of studies have demonstrated that ATF5 is highly Oncotarget 2 www.impactjournals.com/oncotarget
expressed in a variety of cancer cell types, whereas it is 
not detectably expressed in most normal human tissues 
(the exceptions being the liver, prostate and testis, where 
ATF5 is expressed at a high level [6,9]). For example, a 
comparison of ATF5 protein levels between normal and 
neoplastic samples using tissue microarrays revealed 
that in all malignant tissues examinedincluding those 
of the prostate, colon, endometrium, breast, ovary, 
pancreas, gastric, and lungthe percentage of ATF5-
positive cells is significantly higher than that in normal 
tissues [10]. Similarly, a query of the Oncomine cancer 
profiling database revealed that, in general, the expression 
level of ATF5 is significantly higher in malignant tissues 
than their normal counterpart tissues [11]. The only 
exception appears to be hepatocellular carcinoma cells, 
which express lower levels of ATF5 than normal liver 
cells; this discrepancy may be due to epigenetic silencing 
of ATF5 in hepatocellular carcinoma cells through 
promoter methylation [12]. Notably, increased levels of 
ATF5 have been observed in primary brain tumors, and 
ATF5 expression is particularly high in glioblastoma, an 
aggressive form of malignant glioma [10,11].
A pair of studies has provided intriguing evidence 
that high ATF5 expression levels may correlate with poor 
prognosis in cancer patients. In one study, a retrospective 
analysis of 23 individuals with glioblastoma revealed that 
patients harboring tumors expressing high levels of ATF5 
had substantially shorter survival times than those with 
tumors in which ATF5 expression was low or undetectable 
[11].  In  another  study,  expression  profiling  in  chronic 
lymphocytic leukemia (CLL) patients of known clinical 
outcome identified ATF5 as a gene whose significant over-
expression correlates with poor patient outcome [13].
IdEntIFIcAtIon oF An EssEntIAl 
AtF5-MEdIAtEd survIvAl 
pAthwAy In MAlIgnAnt glIoMA: 
thErApEutIc IMplIcAtIons
Inhibition of ATF5 activity, using a dominant 
negative form of ATF5, kills human and rat glioblastoma 
cells but does not affect normal cells surrounding the 
tumor, indicating ATF5 is selectively essential for the 
survival of glioblastoma cells [10]. The high expression 
of ATF5 in brain tumors, combined with the fact that it is 
selectively essential for glioma cell survival, make ATF5 
an appealing potential therapeutic target for the treatment 
of malignant glioma. However, developing effective 
small-molecular inhibitors of transcription factors has 
proven to be challenging [14].
To uncover the upstream signaling pathways that 
control the expression and activity of ATF5—with the 
goal of identifying more targetable proteins, such as 
kinases, required for glioma cell survival—we performed 
a genome-wide RNA interference (RNAi) screen for 
factors that are required for transcription of the ATF5 gene 
[11]. Because loss of ATF5 function within a cell would 
induce apoptosis, and therefore preclude the subsequent 
identification of candidate short hairpin RNAs (shRNAs), 
we developed a novel negative-selection strategy (Figure 
1). This strategy was based on the ability of diphtheria 
toxin (DT) to kill cells that express the DT receptor 
(DTR). Mouse cells lack a functional DTR and are DT 
resistant [15]. We generated a mouse malignant glioma 
GL261 cell line stably expressing the human DTR driven 
by the mouse ATF5 promoter; the ATF5 promoter is 
normally active in GL261 cells, which drives expression 
of the DTR gene and confers susceptibility to DT. We then 
used this stable cell line to screen for shRNAs that could 
inactivate the ATF5 promoter and, consequently, give rise 
to a DT-resistant clone. Because these shRNAs would 
also inhibit expression of the endogenous ATF5 gene 
and induce apoptosis, the cell line was kept alive by the 
expression of ATF5 driven by a constitutive promoter. DT-
resistant clones were isolated, and positive shRNAs were 
identified and then validated for their ability to inhibit 
expression of the endogenous ATF5 gene. 
This  approach  identified  12  genes  as  regulators 
of  ATF5 expression, and further analyses revealed 
the upstream signaling pathways that regulate ATF5 
expression in malignant glioma (summarized in Figure 
2). Cell surface receptors (e.g. fibroblast growth factor 
receptor (FGFR) or epidermal growth factor receptor 
Figure 1: schematic summary of the genome-wide rnAi 
negative-selection screen used to identify factors required 
for transcription of ATF5.  Diphtheria toxin (DT)-resistant 
mouse malignant glioma GL261 cells stably co-expressing the human 
diphtheria toxin receptor (DTR) gene driven by the mouse ATF5 
promoter and ATF5 driven by the constitutive CMV promoter were 
transduced with a genome-wide mouse shRNA library.  DT-resistant 
clones were isolated, and positive shRNAs were identified.
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(EGFR)) activate downstream RAS/mitogen-activated 
protein kinase (RAS/MAPK) or phosphoinositide-3-
kinase (PI3K) signaling pathways through FGFR substrate 
2 (FRS2) and culminate in the activation of CREB protein 
3-like 2 (CREB3L2), which in turn stimulates transcription 
of ATF5. ATF5 then antagonizes apoptosis by directly up-
regulating expression of myeloid cell leukemia sequence 
1 (MCL1), an anti-apoptotic B-cell leukemia/lymphoma 2 
(BCL2) family member.
Pharmacological inhibitors of several components of 
that ATF5-mediated survival pathway are commercially 
available (see Figure 2). One of these inhibitors, sorafenib, 
is a multi-kinase inhibitor whose strongest activity is 
against RAF kinases and has been used to treat several 
different types of cancers [16,17]. Sorafenib inhibits the 
growth of human malignant glioma xenografts in mice, 
which suggests it may also be used to treat malignant 
glioma [11]. Furthermore, sorafenib sensitizes human 
malignant glioma xenografts to temozolomide, a 
chemotherapeutic agent commonly used to treat malignant 
glioma [18]. Inhibition of other components of the ATF5-
mediated survival pathway, including FGFR (using the 
specific inhibitor PD173074), EGFR (CL-387,785), RAS 
(manumycin A), MEK (U0126), ERK (FR180204) and 
PI3K (LY294002), also induces apoptosis in malignant 
glioma cells [11]. Further investigation will verify whether 
these inhibitors may also be used to treat malignant 
glioma.
In addition to glioblastoma, ATF5 is also essential 
for the viability of other cancer cell types. For example, 
inhibition of ATF5 by a dominant negative mutant 
selectively kills breast cancer cells but not normal breast 
epithelial cells [10]. Furthermore, RNAi-mediated 
knockdown of ATF5 induces apoptosis in a variety of 
tumor cell lines derived from lung, prostate, skin, and 
ovary [11]. Taken together these studies demonstrate that 
ATF5 mediates cell survival in many cancers, and suggest 
that inhibition of the ATF5-mediated survival pathway 
may have therapeutic implications for the treatment of a 
wide range of malignancies.
FuturE dIrEctIons
Further investigations will reveal whether the ATF5-
mediated survival pathway represents an efficacious target 
for the treatment of cancers in addition to glioblastoma. 
Likewise, given that ATF5 is aberrantly over-expressed in 
many tumor types, it would be interesting to investigate 
whether high ATF5 expression is generally linked to poor 
prognosis of cancer patients, as has been observed in 
glioblastoma and CLL.
Mechanistically, a further understanding of the 
physiological and pathological role of ATF5 in vivo would 
greatly benefit from the generation of ATF5 knock-out 
mice. If homozygous deletion of the ATF5 gene does not 
result in embryonic lethality, then crossing ATF5 knock-
out mice with mice bearing genetic mutations that induce 
tumorigenesis would ascertain whether ATF5 is essential 
for tumor formation and progression in vivo.
It is possible that ATF5 antagonizes apoptosis 
through multiple targets in addition to MCL1. For example, 
ATF5 has been shown to promote cell survival through 
transcriptional activation of heat shock protein 27 (Hsp27) 
in rat H9c2 cells [19]. Chromatin immunoprecipitation 
coupled with deep sequencing (ChIP-seq) could be used 
to identify ATF5 target genes and study ATF5 function on 
a genome-wide level. Identification of additional ATF5 
target genes would further define the important role of 
ATF5 in cancer development, and may also identify 
additional potential therapeutic targets. 
Finally, it is worth noting that the genome-wide 
Figure 2: An essential AtF5-mediated survival pathway 
in malignant glioma. Cell surface receptors (FGFR or EGFR) 
activate RAS/MAPK or PI3K signaling pathways through FGFR 
substrate 2 (FRS2) and culminate in the activation of CREB3L2, 
which in turn stimulates transcription of ATF5.  ATF5 then antagonizes 
apoptosis by directly up-regulating expression of the anti-apoptotic 
factor MCL1.  Commercially available pharmacological inhibitors 
of several components of the ATF5-mediated survival pathway are 
indicated in gray.
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RNAi negative-selection screening approach used to 
identify components of the ATF5-mediated survival 
pathway represents a general strategy that can be applied 
to identify essential survival pathways in other types of 
cancer cells. Such studies may reveal new regulatory 
pathways that contribute to malignant transformation and 
are potential therapeutic targets.
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